Table 1. Epidemiological, clinical and laboratory features of the 103 patients with erythroderma according to etiology.
| Etiology | Psoriasis n=46, 44.7% | Drug reaction n=19, 18.4% | Eczema n=17, 16.5% | Malignancies n=13, 12.6% | Idiopathic n=4, 3.9% | Others* n=4, 3.9% | Total n=103 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age at admission (years) |
Mean | 50.9 | 61.2 | 46.0 | 69.4 | 51.8 | 51.0 | 54.4 | |||||||
| Range | (17-87) | (22-89) | (22-71) | (37-86) | (36-80) | (28-76) | (17-89) | ||||||||
| Male:Female ratio | 1.6 : 1 | 1 : 1.4 | 2.4 : 1 | 1 : 1 | 1 : 1 | 4 : 0 | 1.5 : 1 | ||||||||
| Erythroderma’s duration before admission (days) | Mean | 40 | 10 | 25 | 20 | 20 | 30 | 12 | |||||||
| Range | 4-150 | 1-20 | 8-90 | 15-60 | 8-45 | 4-40 | (1-150) | ||||||||
| Hospital stay (days) | Mean | 20 | 16 | 14 | 20 | 14 | 14 | 18 | |||||||
| Range | 5-40 | 5-24 | 4-20 | 10-45 | 5-20 | 4-18 | (4-45) | ||||||||
| Clinical findings | n | % | n | % | n | % | n | % | n | % | n | % | n | % | |
| Pruritus | 46 | 100.0 | 17 | 89.5 | 17 | 100.0 | 13 | 100.0 | 4 | 100.0 | 3 | 75.0 | 100 | 97.1 | |
| Peripheral edema | 23 | 50.0 | 12 | 63.2 | 6 | 35.3 | 12 | 92.3 | 3 | 75.0 | 2 | 50.0 | 58 | 56.3 | |
| Fever | 22 | 47.8 | 17 | 89.5 | 5 | 29.4 | 7 | 53.8 | 3 | 75.0 | 2 | 50.0 | 56 | 54.4 | |
| Palmoplantar keratoderma | 32 | 69.6 | 2 | 10.5 | 7 | 41.2 | 10 | 76.9 | 0 | 0.0 | 1 | 25.0 | 52 | 50.5 | |
| Nail changes | 27 | 58.7 | 1 | 5.3 | 4 | 23.5 | 10 | 76.9 | 2 | 50.0 | 0 | 0.0 | 44 | 42.7 | |
| Liver and/or spleen enlargement | 16 | 34.8 | 3 | 15.8 | 9 | 52.9 | 13 | 100.0 | 1 | 25.0 | 1 | 25.0 | 43 | 41.7 | |
| Lymphadenopathy | 14 | 30.4 | 7 | 36.8 | 4 | 23.5 | 13 | 100.0 | 2 | 50.0 | 2 | 50.0 | 42 | 40.8 | |
| Psoriatic arthritis | 19 | 41.3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 19 | 18.4 | |
| Alcohol dependence | 12 | 26.1 | 0 | 0 | 1 | 5.9 | 0 | 0 | 1 | 25.0 | 1 | 25.0 | 15 | 14.6 | |
| Hypertension | 7 | 15.2 | 2 | 10.5 | 2 | 11.8 | 2 | 15.4 | 1 | 25.0 | 1 | 25.0 | 15 | 14.6 | |
| Diabetes | 5 | 10.9 | 1 | 5.3 | 1 | 5.9 | 2 | 15.4 | 1 | 25.0 | 0 | 0 | 10 | 9.7 | |
| Congestive heart failure | 5 | 10.9 | 1 | 5.3 | 0 | 0 | 2 | 15.4 | 0 | 0 | 1 | 25.0 | 9 | 8.7 | |
| Dyslipidemia | 4 | 8.7 | 1 | 5.3 | 0 | 0 | 1 | 7.7 | 1 | 25.0 | 0 | 0 | 7 | 6.8 | |
| Chronic kidney disease | 2 | 4.3 | 1 | 5.3 | 0 | 0 | 2 | 15.4 | 0 | 0 | 0 | 0 | 5 | 4.9 | |
| Epilepsy | 0 | 0 | 5 | 26.3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 4.9 | |
| Laboratory data | n | % | n | % | n | % | n | % | n | % | n | % | n | % | |
| Elevated ESR or CRP | 44 | 95.7 | 19 | 100.0 | 16 | 94.1 | 13 | 100.0 | 4 | 100.0 | 3 | 75.0 | 99 | 96.1 | |
| Leukocytosis | 20 | 43.5 | 13 | 68.4 | 4 | 23.5 | 8 | 61.5 | 2 | 50.0 | 3 | 75.0 | 50 | 48.5 | |
| Eosinophilia | 11 | 23.9 | 8 | 42.1 | 9 | 52.9 | 10 | 76.9 | 2 | 50.0 | 1 | 25.0 | 41 | 39.8 | |
| Anemia | 10 | 21.7 | 7 | 36.8 | 3 | 17.6 | 9 | 69.2 | 2 | 50.0 | 0 | 0.0 | 31 | 30.1 | |
| * Subacute cutaneous lupus (n=1); acquired ichthyosis (n=1); pemphigus foliaceus (n=1); scabies (n=1). | |||||||||||||||